Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  localized unresectable adult primary liver cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 40 for your search:
Start Over
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1112, NCI-2012-02057, NCT01730937
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 104-13-302, NCI-2014-02527, NCT02112656
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15755, NCI-2016-00158, 2014-005068-13, I4T-MC-JVDE, NCT02435433
A Study of Nivolumab Compared to Sorafenib as a Primary Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
Tivozanib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
Hydroxychloroquine Sulfate with TACE in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 22213, NCI-2014-00398, 818625, NCT02013778
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, BBI608-503-103HCC, NCT02279719
Trial of TRC105 and Sorafenib in Patients With HCC
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105HCC101, NCI-2016-00131, NCT02560779
Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-279, NCI-2016-00062, NCT02642913
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13665, NCI-2011-00304, H9H-MC-JBAK, NCT01246986
Sorafenib Tosylate following a Liver Transplant in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-003311, NCI-2012-00911, JCCC-SUPPL-8-2014, ONC-2010-31, NCT01624285
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0870, NCI-2013-01667, Y-90, NCT01900002
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CF102-201HCC, NCI-2016-00211, NCT02128958
A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00022, NCI-2016-00207, NCT02519348
Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-224, NCI-2016-00516, 2015-004566-28, NCT02702414
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Lenalidomide and Sorafenib Tosylate to Treat Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0298, NCI-2011-03283, 1004-05, 1105005453, NCT01348503
Stereotactic Body Radiation Therapy and Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0404, NCI-2013-00564, NCT01801163
Start Over